FolioLanternBeta
ARTVArtiva Biotherapeutics, Inc. · Insider ownership research

Artiva Biotherapeutics, Inc. insiders sold $2.7M in the past 12 months. How much of their stake is that?

Insiders sold $2.7M in the past 12 months.27% was sold under disclosed trading plans, 73% to cover taxes. The largest seller, Fred Aslan (Chief Executive Officer, Director), sold $2.0M.Share-of-stake figures for this company are being verified and will be added when that check is finished. Why

Updated Oct 13, 2026 from SEC filings · covers Oct 14, 2025 to Oct 13, 2026
$2.0M
largest seller, Fred Aslan, past 12 months
27%
of sales were under disclosed trading plans, past 12 months
5 of 14
officers and directors sold shares, past 12 months
Latest filing: Filed Oct 7 for a sale on Oct 6. Fred Aslan sold 23K shares ($169K) under a disclosed plan. Filing
SEC ownership filings: 69 filed in the 12 months to Oct 13, 2026; 122 on record since Jul 18, 2024 · See the evidence

What stands out

Selling picked up in the last 90 days: officers and directors sold 219K shares, against an average of 29K per 90 days earlier in the period. Most of it was Fred Aslan (170K shares in the last 90 days) and Christopher Horan (21K shares in the last 90 days); 26% of these sales were under disclosed plans.Fred Aslan: largest recent sale, Sep 3, 2026 · Christopher Horan: largest recent sale, Sep 3, 2026

A share of stake is shown for 0 of the 5 officers and directors who sold. 14 are left out

i
Left out: Fred Aslan, Jennifer Bush, Neha Krishnamohan, Christopher Horan, Subhashis Banerjee, Heather Raymon, Brian Daniels, Elizabeth Hougen, Laura Stoppel, Gines Miralles, Alison Moore, Daniel Baker, Elaine Sorg and Thad Huston (share of stake is being verified).
Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Fred Aslan
Chief Executive Officer, Director
Not confirmed
Share of stake not shown: share of stake is being verified. Why
$2.0M31% planned, 69% to cover taxes
Christopher Horan
Chief Tech Operations Officer
Not confirmed
Share of stake not shown: share of stake is being verified. Why
$249KTo cover taxes
Jennifer Bush
COO, CLO, Compliance Officer
Not confirmed
Share of stake not shown: share of stake is being verified. Why
$230KTo cover taxes
Subhashis Banerjee
Chief Medical Officer
Not confirmed
Share of stake not shown: share of stake is being verified. Why
$187K56% planned, 44% to cover taxes
Heather Raymon
SVP, Research and Development
Not confirmed
Share of stake not shown: share of stake is being verified. Why
$28KTo cover taxes
Amounts, filings and trading plans for each seller

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled
Oct 2025: $153K under a disclosed planOctNov 2025: $22K under a disclosed planNovDec 2025: $19K under a disclosed planDecJanFebMarAprMay 2026: $478K to cover taxesMayJunJulAug 2026: $104K under a disclosed planAugSep 2026: $256K under a disclosed planSep 2026: $912K to cover taxes$1.2MSepOct 2026: $169K under a disclosed planOct 2026: $557K to cover taxesOct

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026
Oct 6, 2026Fred Aslan sold 23K shares ($169K) under a disclosed trading plan.
WhoSharesPrice% of total stakeTotal stake afterTrade dateFiled
Fred Aslan
Chief Executive Officer, Director
23,463$7.20n/an/aOct 6, 2026Oct 7, 2026
Oct 5, 20264 executives sold 82K shares ($557K) to cover taxes on vesting stock.
WhoSharesPrice% of total stakeTotal stake afterTrade dateFiled
Fred Aslan
Chief Executive Officer, Director
61,696$6.84n/an/aOct 5, 2026Oct 6, 2026
Christopher Horan
Chief Tech Operations Officer
10,340$6.84n/an/aOct 5, 2026Oct 6, 2026
Jennifer Bush
COO, CLO, Compliance Officer
8,370$6.84n/an/aOct 5, 2026Oct 6, 2026
Subhashis Banerjee
Chief Medical Officer
1,099$6.84n/an/aOct 5, 2026Oct 6, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

RA CAPITAL MANAGEMENT, L.P. and GC Corp. reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Artiva Biotherapeutics, Inc. CEO selling stock?

Yes. Fred Aslan sold 233K shares ($2.0M) in the past 12 months, 31% of it under a trading plan disclosed in the filings.

Why are Artiva Biotherapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 27% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 73% were to cover taxes. A trading plan schedules sales in advance.

Are any Artiva Biotherapeutics, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold5 officers and directors: amount, % of holdings, trading plan
Who soldAmount% of holdingsTrading plan
Fred Aslan
Chief Executive Officer, Director
$2.0M
233K shares
Not confirmed
share of stake is being verified. Why
31% under a disclosed plan, 69% to cover taxes
Christopher Horan
Chief Tech Operations Officer
$249K
28K shares
Not confirmed
share of stake is being verified. Why
To cover taxes
Jennifer Bush
COO, CLO, Compliance Officer
$230K
26K shares
Not confirmed
share of stake is being verified. Why
To cover taxes
Subhashis Banerjee
Chief Medical Officer
$187K
18K shares
Not confirmed
share of stake is being verified. Why
56% under a disclosed plan, 44% to cover taxes
Heather Raymon
SVP, Research and Development
$28K
3.1K shares
Not confirmed
share of stake is being verified. Why
To cover taxes

Outside holder, reported separately: RA CAPITAL MANAGEMENT, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: GC Corp. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 14 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

InsiderHeld Oct 13, 2025SoldHeld Oct 13, 2026Still held
Fred Aslan
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Fred Aslan are complete.
Chief Executive Officer, Director
n/a−233Kn/an/a
Vesting, gifts, unvested awards and holding lines for Fred Aslan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Fred Aslan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
−21Kwithheld by the company for taxes

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
343,811$12.00Jul 17, 2034$0
155,000$10.42Sep 9, 2036$0
315,000$8.91Sep 14, 2036$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Jennifer Bush
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jennifer Bush are complete.
COO, CLO, Compliance Officer
n/a−26Kn/an/a
Vesting, gifts, unvested awards and holding lines for Jennifer Bush

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jennifer Bush are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
−6.6Kwithheld by the company for taxes

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
135,000$10.79Sep 8, 2036$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Neha Krishnamohan
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Neha Krishnamohan are complete.
Chief Financial Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Neha Krishnamohan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Neha Krishnamohan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
−3.5Kwithheld by the company for taxes

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
102,599$13.47May 1, 2034$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Christopher Horan
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Christopher Horan are complete.
Chief Tech Operations Officer
n/a−28Kn/an/a
Vesting, gifts, unvested awards and holding lines for Christopher Horan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Horan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
−4.1Kwithheld by the company for taxes

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
120,000$10.79Sep 8, 2036$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Subhashis Banerjee
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Subhashis Banerjee are complete.
Chief Medical Officer
n/a−18Kn/an/a
Vesting, gifts, unvested awards and holding lines for Subhashis Banerjee

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Subhashis Banerjee are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
74,265$1.92Apr 7, 2035$392K
85,000$10.79Sep 8, 2036$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Heather Raymon
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Heather Raymon are complete.
SVP, Research and Development
n/a−3.1Kn/an/a
Vesting, gifts, unvested awards and holding lines for Heather Raymon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Heather Raymon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
−2.9Kwithheld by the company for taxes
Brian Daniels
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Brian Daniels are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Brian Daniels

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brian Daniels are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
13,750$1.61Jun 23, 2035$77K
13,750$10.88Sep 7, 2036$0
16,250$10.42Sep 9, 2036$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Elizabeth Hougen
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Elizabeth Hougen are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Elizabeth Hougen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Elizabeth Hougen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
13,679$5.01Apr 2, 2033$30K
3,419$13.47May 1, 2034$0
13,750$1.61Jun 23, 2035$77K
13,750$10.88Sep 7, 2036$0
16,250$10.42Sep 9, 2036$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Laura Stoppel
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Laura Stoppel are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Laura Stoppel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Laura Stoppel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
13,750$1.61Jun 23, 2035$77K
13,750$10.88Sep 7, 2036$0
16,250$10.42Sep 9, 2036$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Gines Miralles
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Gines Miralles are complete.
President & Head of R&D
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Gines Miralles

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gines Miralles are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
12,995$5.18Jan 23, 2034$26K
13,750$1.61Jun 23, 2035$77K
232,500$9.22May 17, 2036$0
135,000$10.79Sep 8, 2036$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Alison Moore
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Alison Moore are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Alison Moore

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alison Moore are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
27,500$10.48Oct 20, 2034$0
13,750$1.61Jun 23, 2035$77K
13,750$10.88Sep 7, 2036$0
16,250$10.42Sep 9, 2036$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Daniel Baker
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Daniel Baker are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Daniel Baker

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Daniel Baker are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
27,500$5.56Jan 27, 2035$45K
13,750$1.61Jun 23, 2035$77K
13,750$10.88Sep 7, 2036$0
16,250$10.42Sep 9, 2036$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Elaine Sorg
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Elaine Sorg are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Elaine Sorg

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Elaine Sorg are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
27,500$4.15Feb 17, 2036$84K
13,750$10.88Sep 7, 2036$0
16,250$10.42Sep 9, 2036$0

Estimate: options held × ($7.20 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Thad Huston
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Thad Huston are complete.
Chief Financial Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Thad Huston

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Thad Huston are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Holdings and share of stake for Artiva Biotherapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$2.7M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $2.7M across 306,895 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

The lighter segment is sales with no plan disclosed in the filing ($1.9M), including tax-related sales outside a plan.

Taxes

$1.9M of sales (72.9%) cite tax obligations in their footnotes. Separately, 37,989 shares ($140K) were withheld by the company for taxes, which isn't a market sale. Example: Subhashis Banerjee, Oct 5, 2026

SellerShares soldProceedsUnder a disclosed planShare of totalSales dates
Fred Aslan
Chief Executive Officer, Director
233K$2.0M31%74%Oct 17, 2025 to Oct 6, 2026
Christopher Horan
Chief Tech Operations Officer
28K$249K0%9%May 19, 2026 to Oct 5, 2026
Jennifer Bush
COO, CLO, Compliance Officer
26K$230K0%9%May 19, 2026 to Oct 5, 2026
Subhashis Banerjee
Chief Medical Officer
18K$187K56%7%May 19, 2026 to Oct 5, 2026
Heather Raymon
SVP, Research and Development
3.1K$28K0%1%May 19, 2026 to May 19, 2026

Sales by month

MonthSale proceedsDisclosed planTo cover taxesNo plan disclosed
Oct 2025$153K$153K$0$0
Nov 2025$22K$22K$0$0
Dec 2025$19K$19K$0$0
Jan 2026$0$0$0$0
Feb 2026$0$0$0$0
Mar 2026$0$0$0$0
Apr 2026$0$0$0$0
May 2026$478K$0$478K$0
Jun 2026$0$0$0$0
Jul 2026$0$0$0$0
Aug 2026$104K$104K$0$0
Sep 2026$1.2M$256K$912K$0
Oct 2026$726K$169K$557K$0
Known gaps and uncertainty14 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Artiva Biotherapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology122 filings on record, 69 filed in the 12-month period, and how we read them

All 122 Forms 3, 4 and 5 on record for Artiva Biotherapeutics, Inc. (SEC CIK 1817241), filed from Jul 18, 2024 to Oct 7, 2026; 69 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (6)No filing in 18 months; last reported balances, not in any total
NameLast filedLast reported balance
Thorsten GraefFeb 28, 202580,000 shares, last reported balance as of Feb 26, 2025
5AM Partners VI, LLCJul 24, 20242,353,304 shares, last reported balance as of Jul 22, 2024
Yong-Jun HuhJul 22, 20244,567,412 shares, last reported balance as of Jul 22, 2024
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Jul 22, 2024194,108 shares, last reported balance as of Jul 22, 2024
venBio Global Strategic Fund III, L.P.Jul 22, 20241,936,637 shares, last reported balance as of Jul 22, 2024
Laura BessenJul 18, 2024No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.